Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region

Fibrinolysis

Volumn 13, Issue 1, 1999, Pages 26-30

  Falk, G ^a   Sui, G C ^a   Schulman, S ^a   Wiman, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THREONINE;

ALLELISM; ARTICLE; BLEEDING TENDENCY; DNA POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFICIENCY; RNA SPLICING;

EID: 0032923839     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(99)90012-7     Document Type: Article

References (22)

1. Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Curr Opin Hematol 1996; 3: 372-378.
2. Aoki N, Sakata Y, Matsuda M, Tateno K. Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor. Blood 1980; 55: 483-488.
3. Saito H. Alpha 2-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112: 671-678.
4. Stankiewicz AJ, Crowley JP, Steiner M. Increased levels of tissue plasminogen activator with a low plasminogen activator inhibitor-1 in a patient with postoperative bleeding. Am J Hematol 1991; 38: 226-229.
5. Wiman B, Chmielewska J, Rànby M. Inactivation of tissue plasminogen activator in plasma: Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647.
6. Eriksson B, Eriksson E, Gyzander E, Teger-Nilsson AC, Thorsen S, Risberg B. Thrombosis after hip replacement, relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159-163.
7. Schulman S, Wiman B, for the Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous tromboembolism. Thromb Haemostas 1996; 75: 607-611.
8. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
9. Cortellaro M, Cofrancesco E, Boscheti C et al. For the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients - a case-control study. Arteriosclerosis Thromb 1993; 13: 1412-1417.
10. Held C, Hjelmdahl P, Rehnqvist N et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997; 95: 2380-2386.
11. Lee MH. Vosburgh E. Anderson K. McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-2362.
12. Takahashi Y, Tanaka T, Minowa H et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol 1996; 64: 61-68.
13. Fay WP, Parker AC, Condrey LR. Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterzation of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-208.
14. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis Thromb 1991; 11: 183-190.
15. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
16. Nordenhem A, Wiman B. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. Scand J Clin Lab Invest 1997; 57: 453-462.
17. Eriksson P, Kallin B, van't Hooft FM, Bàvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855.
18. Ye S, Green FR, Scarabin PY et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-841.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
20. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone, Pennelli O, Di MG. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arteriosclerosis, Thrombosis & Vascular Biology 1998; 18: 152-156.
21. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 1998; 58: 1-8.
22. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263: 9129-9141.